Table 1 Characteristics of included studies
Trial or Author | Time | Design | SGLT2i | Control | Number (I/C) | Follow up time | LVEF |
|---|---|---|---|---|---|---|---|
DAPA-HF [3] | 2019 | RCT | DAPA 10 mg once daily | Placebo | 2373/2371 | 18.2 months | LVEF ≤ 40% |
DEFINE-HF [19] | 2019 | RCT | DAPA 10 mg once daily | placebo | 131/132 | 12 Weeks | LVEF ≤ 40% |
De Boer [31] | 2019 | RCT | Licogliflozin (2.5 mg, 10 mg, 50 mg) EMPA 25 mg once daily | Placebo | 91/33 | 12 Weeks | NR |
MUSCAT‐HF [30] | 2019 | open-label RCT | Luseogliflozin 2.5 mg once daily | voglibose 0.2 mg Three times a day | 83/82 | 12 Weeks | LVEF ≥ 45% |
REFORM [20] | 2019 | RCT | DAPA 10 mg once daily | placebo | 28/28 | 1 year | NR |
CANDLE [27] | 2020 | open-label RCT | CANA 100 mg once daily | Glimepiride 0.5 mg once daily | 113/120 | 24 Weeks | NR |
CANA-HF [28] | 2020 | RCT | CANA 100 mg once daily | sitagliptin 100 mg once daily | 17/19 | 12 Weeks | LVEF ≤ 40% |
EMPEROR-Reduced [4] | 2020 | RCT | EMPA 10 mg once daily | Placebo | 1863/1867 | 16 months | LVEF ≤ 40% |
EMPEROR-Preserved [22] | 2021 | RCT | EMPA 10 mg once daily | placebo | 2997/2991 | 26.2 months | LVEF > 40% |
EMBRACE-HF [23] | 2020 | RCT | EMPA 10 mg once daily | placebo | 33/32 | 12 Weeks | NR |
RECEDE-CHF [18] | 2020 | cross-over RCT | EMPA 25 mg once daily | Placebo | 12/11 | 6 Weeks | LVEF < 50% |
CANONICAL [29] | 2021 | open-label RCT | CANA 100 mg once daily | NR | 42/40 | 24 Weeks | LVEF ≥ 50% |
Empire HF [24] | 2021 | RCT | EMPA 10 mg once daily | placebo | 95/95 | 12 Weeks | LVEF ≤ 40% |
PRESERVED-HF [21] | 2021 | RCT | DAPA 10 mg once daily | placebo | 162/162 | 12 Weeks | LVEF ≥ 45% |
Pietschner [25] | 2021 | RCT | EMPA 10 mg once daily | placebo | 36/17 | 12 Weeks | LVEF < 50% |
SUGAR-DM-HF [26] | 2021 | RCT | EMPA 10 mg once daily | placebo | 52/53 | 36 Weeks | LVEF ≤ 40% |